Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ: IPHA )

1.996 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 717
Open 1.996
Bid (Size) 2.000 (2)
Ask (Size) 2.080 (3)
Prev. Close 1.996
Today's Range 1.996 - 1.996
52wk Range 1.290 - 3.511
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Innate Pharma Announces €15M Investment by Sanofi
From Innate Pharma SA
Via Business Wire
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
From Innate Pharma SA
Via Business Wire

Performance

YTD
+6.71%
+6.71%
1 Month
+1.43%
+1.43%
3 Month
+12.74%
+12.74%
6 Month
+3.39%
+3.39%
1 Year
-15.80%
-15.80%

More News

Read More
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
From Innate Pharma SA
Via Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
Earnings Scheduled For March 27, 2025
Via Benzinga
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
Wondering what's happening in today's pre-market session?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
From Innate Pharma SA
Via Business Wire
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Topics Economy
Exposures Supply Chain
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Transformative Strategy to Accelerate Growth
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.